Our Vision
We are charting a path to become the leading targeted topical therapeutics development company by leveraging decades of combined team experience to select and develop first-in-class assets with the highest probability of success in the clinic and to run efficient clinical trials at a fraction of industry standard timelines and budgets.
Small Molecules
DermBiont is advancing targeting topical small molecules for the treatment of skin diseases, beginning with SM-020 for the treatment of laBCC and prevention of BCC in Gorlin Syndrome patients as well as SM-030 for the treatment of melasma.